Several factors, including IL-28B genotype, low baseline HCV RNA, less severe liver fibrosis, age and BMI have been reported as pre-treatment predictors of treatment responses among patients undergoing PEG-IFN-based therapy [3, 40, 41]. The gene discussed is IFNA1; the disease is Hepatic fibrosis.